Renal Protective Effect of Metformin in Type 2 Diabetes Patients
Authors' conclusion
Metformin decreased the risk of renal function deterioration.
Study context
- Population
- Patients with T2D from 7 hospitalsmatched cohort
- Participants
- 316,693 patients
- Exposure
- Metformin vs non-metformin
- Metforminn = 13,096
- Non-metforminn = 13,096reference
- Outcome
- Doubling of serum creatinine, eGFR ≤ 15 mL/min/1.73 m² and end-stage kidney disease (ESKD)
Methodological detailsmulticenter, matched on age, gender, medical year, baseline estimated glomerular filtration rate (eGFR), urine protein, HbA1c and propensity score
- Multicenter
- Matched on age, gender, medical year, baseline eGFR, urine protein, HbA1c and propensity score
Main finding
As reported in the abstract
Doubling of serum creatinine; eGFR ≤ 15 mL/min/1.73 m²; ESKD
Metformin vs Non-metforminHazard ratio (95% CI)
Doubling of serum creatinine
0.71(0.65–0.77)
eGFR ≤ 15 mL/min/1.73 m²
0.61(0.53–0.71)
ESKD
0.55(0.47–0.66)
Observational data: associations, not effects.
Further findings
Subgroup analyses
- Consistent renoprotective effect across various renal functions; slower renal function deterioration with metformin across nearly all subgroups (age, sex, comorbidities, medications)
Original publication
Renal Protective Effect of Metformin in Type 2 Diabetes Patients. J Clin Endocrinol Metab. Published 11 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →